Innovating Works

BioNTech IMFS

Desconocido
AML-VACCiN: Clinical development of a dendritic cell vaccine therapy for acute myeloid leukaemia BIONTECH INNOVATIVE MANUFACTURING SERVICES GMBH participó en un H2020: H2020-PHC-2014-2015 Eradicating minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML) is an area of high unmet medical need. AML is a de...
2015-12-09 - 2020-09-30 | Financiado
CELL-PID: Advanced Cell based Therapies for the treatment of Primary ImmunoDeficiency BIONTECH INNOVATIVE MANUFACTURING SERVICES GMBH participó en un FP7: Primary immune deficiencies (PID) are inherited disorders of the adaptive and innate immune system marked by severe infections, autoimmunity...
Financiado
PERSIST: Persisting Transgenesis BIONTECH INNOVATIVE MANUFACTURING SERVICES GMBH participó en un FP7: For many disabling or fatal diseases, there is pre-clinical or clinical evidence of the potential therapeutic efficacy of gene therapy and,...
Financiado
GENEGRAFT: Phase I II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using... BIONTECH INNOVATIVE MANUFACTURING SERVICES GMBH participó en un FP7: RDEB is one of the most severe rare genetic skin diseases of children and adults characterized by skin blistering resulting from lack of ex...
Financiado
NET4CGD: Gene Therapy for X linked Chronic Granulomatous Disease CGD BIONTECH INNOVATIVE MANUFACTURING SERVICES GMBH participó en un FP7: This project is focused on the clinical development of a new orphan drug that can rapidly become a new treatment option for patients with th...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.